Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 nivolumab plus ipilimumab in previously treated classical Kaposi sarcoma
MOH_2018-02-05_002165Phase 2Not yet recruiting
- Sponsor
- ד"ר אלונה זר
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in Kaposi sarcoma (KS), sponsored by ד"ר אלונה זר. Primary endpoint: Overall response rate. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on MOH_2018-02-05_002165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-05_002165.